Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to assess the safety and efficacy of high dose and low
dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks
to children and adolescents with mildly-to-moderately active ulcerative colitis.